C000157187 Performance — ProShares UltraPro Nasdaq Biotechnology
Data updated: 2020-04-28
In the 12 months to Feb 2020 the fund lost a net $10.3M, and assets reached $20.23M.
C000157187 Growth of $100
What $100 invested in ProShares UltraPro Nasdaq Biotechnology grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | C000157187 | Category average |
|---|---|---|
| Since data start (Sep 2019 – Feb 2020) | $127 | $101 |
C000157187 Annual Returns
Calendar-year total returns of ProShares UltraPro Nasdaq Biotechnology, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2020 (Jan–Feb) | −17.58% |
| 2019 (Sep–Dec) | +54.51% |
C000157187 Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | −16.8% | −0.9% | — | — | — | — | — | — | — | — | — | — |
| 2019 | — | — | — | — | — | — | — | — | −10.4% | +23.5% | +37.0% | +1.9% |
C000157187 Risk
Risk measures from monthly returns over Sep 2019 – Feb 2020.
- Best month: +37.04% (Nov 2019)
- Worst month: −16.82% (Jan 2020)
C000157187 Fund Flows
Monthly money in and out of ProShares UltraPro Nasdaq Biotechnology, from SEC Form N-PORT.
- 12-month net flow: −$10.3M
- 12-month gross sales (incl. reinvestments): $1.8M
- Sales ÷ redemptions: 0.15×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Feb 2020 | $0 | $1.7M | −$1.7M |
| Jan 2020 | $0 | $1.6M | −$1.6M |
| Dec 2019 | $0 | $0 | $0 |
| Nov 2019 | $0 | $5.4M | −$5.4M |
| Oct 2019 | $1.8M | $2.3M | −$522K |
| Sep 2019 | $0 | $1.1M | −$1.1M |
C000157187 Assets Under Management
Net assets of ProShares UltraPro Nasdaq Biotechnology by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2020-02-29 | $20.23M |
| 2019-11-30 | $27.29M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.